-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Evolving Standards of Care
-
Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication
By Mizuki Nishino, MD, MPH Posted: April 16, 2020 Dr. Mizuki Nishino Artificial intelligence (AI) approaches have emerged as promising tools to address important unmet needs across different specialties in medicine, including oncology, radiology, and pathology. Recent studies have described the utility of AI in lung cancer to improve detection, diagnosis, and prognostication. Many of…
-
Grappling with Coronavirus (SARS-CoV-2)
By Corey J. Langer, MD, ILCN Editor Posted: April 16, 2020 Dr. Corey Langer Michele Carbone MD, Ph.D and colleagues have penned a far-ranging editorial, now published online in the Journal of Thoracic Oncology (JTO), on the “Facts, Myths, and Hypotheses” behind this pandemic and global public health crisis, which was first documented in Hubei…
-
Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of advanced oncogene-driven NSCLC.1,2 Despite initial high response rates, durable and complete responses are rare, and most patients eventually experience treatment failure.3 Residual disease is defined…
-
Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia
Posted: February 12, 2020 Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and other oncogenic drivers has helped further lung cancer research and patient care. In the…
-
TRK Inhibition in TRK Fusion–Positive Lung Cancers
By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. These fusions are found at high frequencies (> 90% in select series) in rare cancers such as secretory carcinoma and at lower frequencies in more…
-
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr. Edgardo S. Santos Castillero
Posted: February 12, 2020 Edgardo S. Santos Castillero, MD, FACP, is an IASLC Lung Cancer News Editorial Group Member and served as a co-chair on the expert panel that developed the American Society of Clinical Oncology (ASCO) Lung Cancer Surveillance After Definitive Curative-Intent Therapy guideline.1 In the following interview, Dr. Santos Castillero discusses key takeaways…
-
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced NSCLC, with prolonged duration of response and significant 5-year survival rates not seen with combination platinum-based chemotherapy.1-6 CheckMate 012, CheckMate 568, and CheckMate 227 are…
-
Smoking Ban in Austria Passed After Years of Political Wrangling
Posted: February 12, 2020 November 1, 2019—After years of political volleying and public outcry, Austria implemented a full indoor smoking ban in bars, cafes, and restaurants. With its capitol, Vienna, consistently being voted “the most livable city in the world” according to an index compiled by the Economist Intelligence Unit,1 the decrease in Austria’s smoking…
-
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019;79(6):1204-1213. Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint…
-
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…